Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 13/20 | 0.67 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2104157 | 0.89 | SYK (0.64) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL2105369 | 0.89 | SYK (0.68) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL2104371 | 0.89 | SYK (0.68) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL13007743 | 0.83 | SYK (0.72) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL2103229 | 0.81 | SYK (0.70) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL13007744 | 0.81 | SYK (0.60) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL653843 | 0.81 | SYK (0.80) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL190515 | 0.80 | SYK (0.61) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL2102893 | 0.80 | SYK (0.57) | SYKJAK2EGFRLCKLYN | |
| SCHEMBL13007738 | 0.80 | SYK (0.49) | SYKJAK2EGFRLCKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851480-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851480-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7557207-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557207-B2 | Spiro 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090062270-A1 | SPIRO 2,4 PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062270-A1 | SPIRO 2,4 PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062270-A1 | SPIRO 2,4 PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | SSB, SPHK2, PKD2 | SYK 1168/4885JAK2 2515/4885EGFR 4643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.